Introduction
If you've spent any time researching peptide science, you've likely run into two names that keep showing up in the same breath: AOD9604 and CJC-1295. Both trace their origins back to human growth hormone research. Both are frequently discussed in fat-loss and body-composition contexts. And both are commonly sold under research-use-only labeling rather than as approved medications.
Featured Products
But "discussed together" doesn't mean "clinically equivalent." AOD9604 and CJC-1295 were developed for different purposes, tested in different trial designs, and produced very different data sets. One is a growth hormone fragment aimed at fat metabolism. The other is a long-acting growth hormone-releasing hormone (GHRH) analog aimed at raising GH and IGF-1 output from the pituitary gland.
This article walks through what the published clinical trials, safety reviews, and regulatory filings on AOD9604 and CJC-1295 actually report — not marketing claims, not forum anecdotes, but the underlying research record. By the end, you'll understand how each compound works, what the human trial data shows, where the evidence is strong versus thin, and what the current U.S. regulatory status looks like for both.
Quick Answer: AOD9604 vs CJC-1295 in Brief
AOD9604 is a 16-amino-acid fragment of human growth hormone (hGH 176-191) originally developed as an anti-obesity drug. Human trials showed modest, statistically significant weight loss (roughly 2-3 kg over 12 weeks) at low doses, but a later, larger trial with structured diet and exercise did not reproduce that effect, and pharmaceutical development was discontinued in 2007. CJC-1295 is a long-acting GHRH analog that stimulates the pituitary to release growth hormone. Its human trial data centers on endocrine biomarkers — GH and IGF-1 elevation lasting 6-11 days after a single dose — rather than body-composition or clinical outcome data. Neither compound has FDA approval for any indication, and both are subject to ongoing U.S. regulatory scrutiny. |
What Is AOD9604? Origin and Mechanism
AOD9604 (the name stands for "Anti-Obesity Drug") is a synthetic fragment corresponding to amino acids 176-191 at the C-terminal end of the human growth hormone molecule. It was engineered to isolate the region of hGH believed to be responsible for stimulating fat breakdown, while excluding the portions of the molecule linked to tissue growth and insulin resistance.
Mechanistically, AOD9604 is understood to act primarily through beta-3 adrenergic receptors concentrated in adipose (fat) tissue. Activation of this pathway upregulates hormone-sensitive lipase, an enzyme that breaks down stored triglycerides into free fatty acids and glycerol — a process called lipolysis. Preclinical research in obese rodent models found that AOD9604 increased beta-3 receptor expression toward levels seen in lean animals, which is the biological rationale behind its fat-metabolism claims.
Key facts about AOD9604
- Developed by Metabolic Pharmaceuticals Ltd. (Australia), with roughly $50 million invested in its clinical program.
- Six human clinical trials were conducted between roughly 2001 and 2007, involving on the order of 900 participants combined.
- It does not appear to be a full growth hormone analog — its design specifically excludes the growth-promoting and glucose-affecting regions of hGH.
- It has also been explored outside obesity research, including in osteoarthritis and cartilage-repair studies, though that evidence base is smaller.
What Is CJC-1295? Origin and Mechanism
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), built from the first 29 amino acids of the native GHRH sequence — the minimum segment needed for full receptor activity. It was developed by ConjuChem Biotechnologies in the mid-2000s to solve a specific problem: natural GHRH is broken down in the bloodstream within minutes, making it clinically impractical.
CJC-1295 addresses that limitation with a Drug Affinity Complex (DAC) — a chemical modification that lets the peptide bind covalently to circulating albumin, extending its half-life to roughly six to eight days. Structurally, it also carries four amino-acid substitutions designed to resist enzymatic degradation. The compound works by binding GHRH receptors on somatotroph cells in the anterior pituitary, triggering a cAMP signaling cascade that increases GH synthesis and release. Notably, published research found that pituitary GH secretion remains pulsatile — rather than flatly elevated — even during continuous CJC-1295 exposure.
Key facts about CJC-1295
- Two forms exist: CJC-1295 with DAC (long-acting, weekly dosing in trials) and CJC-1295 without DAC, also called Modified GRF 1-29 (short-acting).
- The DAC version, used in the published human studies, is the one most often referenced in the clinical literature.
- It acts upstream of growth hormone itself — it stimulates the pituitary to release more GH, rather than supplying GH directly.
- CJC-1295 is listed under Section S2 of the WADA Prohibited List as a peptide hormone/growth factor, prohibited for athletes at all times.
AOD9604: What the Human Clinical Trials Actually Found
AOD9604's evidence base is unusually well-documented for a peptide in this space, precisely because it went through a formal pharmaceutical development pathway before being shelved.
The Phase 2b efficacy trial
The most-cited AOD9604 study was a randomized, double-blind, placebo-controlled Phase 2b trial in roughly 300 obese adults across multiple sites, comparing placebo against oral doses of 1 mg, 5 mg, 10 mg, 20 mg, and 30 mg over 12 weeks. The counterintuitive finding was that the lowest dose — 1 mg daily — produced the largest effect: participants in that group lost an average of roughly 2.6-2.8 kg, compared with about 0.8 kg on placebo. The trial also reported improvements in cholesterol profile and glucose tolerance in the treated groups, and no evidence of the rapid post-treatment weight rebound seen with some other weight-loss drugs.
Where the evidence gets weaker
A subsequent, larger trial that incorporated a structured diet and exercise program did not reproduce the earlier weight-loss signal. According to safety and metabolism reviews of the compound's development history, effects seen in the initial trials were "not seen in the last study in which an intensive diet and exercise regime was incorporated." Metabolic Pharmaceuticals discontinued the drug's development as a prescription obesity treatment in 2007 after this mixed result, despite AOD9604 being consistently well-tolerated with no significant adverse events across all six human trials.
Featured-snippet answer: Does AOD9604 work for weight loss? Early Phase 2 trials found AOD9604 produced modest but statistically significant weight loss (about 2.6-2.8 kg over 12 weeks) versus placebo. A later, larger trial with diet and exercise controls did not confirm this effect, and the drug's development for obesity was discontinued in 2007. |
CJC-1295: What the Human Clinical Trials Actually Found
CJC-1295's human evidence looks different in kind from AOD9604's. Rather than body-composition or weight-loss endpoints, the published trials measured endocrine biomarkers — specifically GH and IGF-1 levels.
The 2006 Teichman trial
The foundational study, published in the Journal of Clinical Endocrinology & Metabolism (2006), was a randomized, placebo-controlled Phase 1 trial in healthy adults. A single subcutaneous dose of CJC-1295 with DAC (ranging from 1 to 30 mcg/kg in the ascending-dose arm) produced dose-dependent GH elevations of roughly 2- to 10-fold above baseline, with effects persisting for six days or more, and IGF-1 elevations of roughly 1.5- to 3-fold that lasted 9 to 11 days. A companion analysis from the same research program confirmed that repeated dosing sustained these elevations while preserving the pituitary's natural pulsatile GH release pattern, rather than flattening it into constant output.
What the data does not show
It's worth being precise here: the published CJC-1295 literature is almost entirely pharmacokinetic and pharmacodynamic — it documents hormone-level changes, not downstream clinical outcomes like fat loss, lean mass gain, sleep quality, or longevity. A small, unpublished conference abstract explored once-weekly CJC-1295 dosing in HIV-associated visceral obesity, but this has not translated into a robust, peer-reviewed clinical-outcomes evidence base. Reviews of the compound's research history consistently note that claims about body composition, anti-aging effects, or muscle growth extend well beyond what the controlled human data actually measured.
Featured-snippet answer: What does CJC-1295 research actually measure? Published CJC-1295 human trials measure growth hormone and IGF-1 blood levels after dosing, not body-composition or clinical outcomes. A single dose raised GH 2- to 10-fold and IGF-1 1.5- to 3-fold, with effects lasting up to 11 days. There is no robust peer-reviewed evidence yet linking this to fat loss, muscle gain, or anti-aging outcomes in humans. |
AOD9604 vs CJC-1295: Side-by-Side Comparison
Factor | AOD9604 | CJC-1295 |
|---|---|---|
Origin | Fragment of human growth hormone (hGH 176-191) | Synthetic analog of GHRH (first 29 amino acids) |
Primary mechanism | Beta-3 adrenergic receptor activation; lipolysis | GHRH receptor activation on pituitary somatotrophs |
Studied endpoint | Body weight, waist circumference, lipid/glucose markers | GH and IGF-1 blood levels (biomarkers) |
Human trials | Six trials, ~900 participants, 2001-2007 | Phase 1 trials in healthy adults, 2006 onward |
Reported human data | Modest weight loss in early trials; not reproduced in later, larger trial | Dose-dependent GH/IGF-1 elevation lasting 6-11 days |
Route studied | Oral (in the pivotal efficacy trials) | Subcutaneous injection |
Pharma development status | Discontinued as an obesity drug in 2007 | No completed pivotal trials or FDA submission on record |
U.S. regulatory status | Not FDA-approved; not a lawful supplement ingredient | Not FDA-approved; flagged in FDA warning letters |
Safety Signals in the Published Research
AOD9604
Across the six completed human trials, AOD9604 was consistently reported as safe and well tolerated, with no evidence of antibody formation (suggesting low immunogenicity) and no meaningful negative effect on carbohydrate metabolism. That said, "well tolerated in trials of this size and duration" is not the same as a full long-term safety profile, and the compound never completed the additional trials that would typically be required for approval.
CJC-1295
The safety picture for CJC-1295 is less complete. Regulatory reviews have flagged a risk of increased heart rate and cardiac effects, and unapproved, non-pharmaceutical-grade sourcing introduces additional variables — impurities and immune reactions — that are separate from the peptide's own pharmacology. FDA correspondence has also referenced adverse findings in nonclinical (animal/cell-based) studies that warrant caution, and the agency has issued warning letters to compounding pharmacies and sellers over unapproved CJC-1295 products.
Common mistake to avoid Treating "well tolerated in short clinical trials" as equivalent to "proven safe for ongoing personal use" is a common misreading of this literature. Trial tolerability data reflects a specific dose, duration, population, and pharmaceutical-grade formulation — it does not establish long-term safety, and it does not apply to unregulated, non-pharmaceutical-grade material sourced outside a controlled research setting. |
U.S. Regulatory Status: What Buyers and Researchers Should Know
As of 2026, neither AOD9604 nor CJC-1295 is an FDA-approved drug for any indication in the United States. Both fall outside the Dietary Supplement Health and Education Act (DSHEA) framework, meaning they cannot lawfully be marketed as dietary supplements. The FDA has issued warning letters to compounding pharmacies and online sellers regarding unapproved peptide products, including CJC-1295, and has cited concerns around impurities, immunogenicity, and insufficient human safety data.
There has also been active regulatory discussion in 2025-2026 around reclassifying certain peptides for compounding purposes, with CJC-1295 and AOD-9604 among the substances referred to the FDA's Pharmacy Compounding Advisory Committee for review. It's important to separate two distinct things: compounding-pharmacy reclassification for prescriber-directed use, and the "research use only" labeling used by many online sellers. Labeling a product "for research use only" does not, by itself, make it lawful to sell or use for human consumption — U.S. regulators and legal analysts have specifically flagged this labeling practice as a point of scrutiny, not a compliance shield.
If your interest in AOD9604 or CJC-1295 is genuinely research-based, that work should take place within an appropriate institutional or laboratory setting, following applicable federal and state regulations. If your interest is personal health or body composition, the responsible next step is a conversation with a licensed physician about FDA-approved options and legitimate medical pathways.
Common Mistakes When Interpreting This Research
- Assuming the two peptides are interchangeable because they're both discussed in "fat loss" or "anti-aging" content — their mechanisms, trial designs, and evidence types are fundamentally different.
- Citing early, small AOD9604 trials while ignoring that the larger, diet-and-exercise-controlled trial did not confirm the effect.
- Treating CJC-1295's hormone-level data as proof of body-composition or performance outcomes, when the published trials didn't measure those outcomes.
- Overlooking that "research use only" labeling is a marketing convention, not a legal designation that authorizes human use.
- Relying on non-peer-reviewed blog claims instead of the original journal publications and regulatory filings cited in this article.
Key Takeaways
- AOD9604 is a growth hormone fragment studied for fat metabolism; CJC-1295 is a GHRH analog studied for GH/IGF-1 stimulation — they are not directly comparable, interchangeable compounds.
- AOD9604's strongest human evidence is a 12-week Phase 2b trial showing modest weight loss at a 1 mg dose, an effect not reproduced in a later, larger trial with diet and exercise controls.
- CJC-1295's human evidence is centered on GH and IGF-1 biomarker elevation lasting up to 11 days after a single dose — not clinical outcomes like fat loss or muscle gain.
- Both compounds were reported as generally tolerable in their respective trials, but neither has completed the safety and efficacy program required for FDA approval.
- Neither AOD9604 nor CJC-1295 is FDA-approved or a lawful dietary supplement ingredient in the United States as of 2026; "research use only" labeling does not change that status.
Frequently Asked Questions
Is AOD9604 the same as human growth hormone?
No. AOD9604 is a small fragment representing only part of the hGH molecule (amino acids 176-191), engineered to isolate the region associated with fat metabolism while excluding the growth-promoting and blood-sugar-affecting portions of full hGH.
Did AOD9604 pass FDA approval for weight loss?
No. AOD9604 completed six human trials but was never approved by the FDA. Its developer discontinued the obesity-drug program in 2007 after a larger trial failed to reproduce earlier weight-loss results.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC includes a Drug Affinity Complex that binds to albumin in the blood, extending its half-life to roughly six to eight days. CJC-1295 without DAC (also called Modified GRF 1-29) lacks this modification and is cleared much faster.
Does CJC-1295 research show fat-loss or muscle-building effects?
The published, peer-reviewed human research on CJC-1295 measures growth hormone and IGF-1 blood levels, not body-composition outcomes. Claims about fat loss, muscle gain, or anti-aging effects go beyond what the controlled trial data actually measured.
Is CJC-1295 legal in the United States?
CJC-1295 is not FDA-approved for any human indication and is not a lawful dietary supplement ingredient. The FDA has issued warning letters concerning unapproved compounded and retail CJC-1295 products.
Is AOD9604 legal to sell as a supplement?
No. AOD9604 is not FDA-approved and does not meet the legal definition of a dietary supplement ingredient under DSHEA, regardless of "research use only" labeling.
Which peptide has stronger clinical evidence, AOD9604 or CJC-1295?
They aren't measuring the same thing, so "stronger" depends on the question. AOD9604 has more clinical-outcome data (weight, waist circumference, lipids) but with mixed results across trials. CJC-1295 has consistent, well-replicated biomarker data (GH/IGF-1 elevation) but very little clinical-outcome data.
What were the doses used in the AOD9604 Phase 2b trial?
The pivotal 12-week trial tested six oral dose groups: placebo, 1 mg, 5 mg, 10 mg, 20 mg, and 30 mg daily. The 1 mg group showed the largest weight-loss effect.
How long do the effects of a single CJC-1295 dose last?
In the 2006 Teichman trial, a single subcutaneous dose of CJC-1295 with DAC raised GH levels for about six days or longer and IGF-1 levels for roughly 9 to 11 days.
Does "research use only" labeling make a peptide legal to use on yourself?
No. Regulatory and legal analysts have specifically identified "research use only" labeling as a labeling convention used by sellers, not a legal authorization for human consumption. The underlying compound's approval status doesn't change based on how it's labeled.
Are AOD9604 and CJC-1295 banned in sports?
CJC-1295 is explicitly listed under the WADA Prohibited List (Section S2, peptide hormones and growth factors), banned at all times for athletes. Unapproved peptides generally fall under WADA's catch-all S0 category even when not individually named.
What side effects have been reported for these two peptides?
AOD9604 trials reported good tolerability with no significant adverse events and no antibody formation. CJC-1295 has been associated in regulatory reviews with potential cardiac effects (such as increased heart rate), along with general risks tied to impurities and immune response in non-pharmaceutical-grade material.
Can I buy AOD9604 or CJC-1295 for personal use in the U.S.?
Both compounds are commonly sold labeled "for research use only," but neither is FDA-approved for human use, and using them outside an authorized research or medical setting raises legal and safety concerns. Speak with a licensed physician about approved alternatives if you have a health goal in mind.
